undamentalytics Newsletter
Sign in

Autolus Therapeutics plc cash flow statement

In fiscal 2025, Autolus Therapeutics plc's operations generated −$284m of cash; it spent $19.0m on capital projects, leaving free cash flow of −$303m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Sept 20162017Sept 20172018Sept 20182019Dec 20192023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−10−16−32−101−146−206−284−226
Depreciation and amortisation01257889
Stock-based pay2373011151415
Capital spending239181122197
Free cash flow−12−19−41−120−157−228−303−233
Free cash flow after stock pay−14−22−47−150−168−244−317−248
Shares issued3212815711605500—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AUTL vs RCUSAUTL vs SPRYAUTL vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Autolus Therapeutics plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Autolus Therapeutics plc.